WealthPLAN Partners’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-7,010
Closed -$545K 275
2025
Q3
$545K Buy
+7,010
New +$548K 0.08% 167
2023
Q3
Sell
-248
Closed -$23.4K 556
2023
Q2
$23.4K Sell
248
-17
-6% -$1.48K ﹤0.01% 646
2023
Q1
$21.9K Sell
265
-6,938
-96% -$545K ﹤0.01% 705
2022
Q4
$552K Buy
+7,203
New +$555K 0.04% 242
2022
Q1
$787K Hold
7,437
0.05% 194
2021
Q4
$812K Hold
7,437
0.05% 196
2021
Q3
$859K Buy
7,437
+17
+0.2% +$1.94K 0.06% 185
2021
Q2
$825K Buy
7,420
+21
+0.3% +$1.98K 0.06% 175
2021
Q1
$690K Buy
+7,399
New +$626K 0.05% 187
2020
Q4
Sell
-7,167
Closed -$576K 343
2020
Q3
$576K Sell
7,167
-207
-3% -$16.2K 0.06% 183
2020
Q2
$585K Hold
7,374
0.06% 167
2020
Q1
$534K Buy
7,374
+138
+2% +$9.95K 0.07% 148
2019
Q4
$547K Buy
7,236
+51
+0.7% +$3.98K 0.06% 157
2019
Q3
$580K Buy
7,185
+42
+0.6% +$2.95K 0.08% 140
2019
Q2
$522K Sell
7,143
-3,672
-34% -$222K 0.08% 143
2019
Q1
$639K Buy
10,815
+90
+0.8% +$5.14K 0.1% 136
2018
Q4
$636K Buy
10,725
+210
+2% +$10.6K 0.1% 131
2018
Q3
$524K Buy
10,515
+615
+6% +$30.1K 0.1% 139
2018
Q2
$480K Buy
9,900
+225
+2% +$10.5K 0.1% 141
2018
Q1
$450K Buy
9,675
+1,755
+22% +$76.2K 0.1% 150
2017
Q4
$298K Buy
7,920
+915
+13% +$33.6K 0.08% 158
2017
Q3
$255K Buy
7,005
+105
+2% +$4K 0.07% 159
2017
Q2
$272K Buy
6,900
+4,950
+254% +$181K 0.08% 143
2017
Q1
$60.5K Buy
+1,950
New +$61.1K 0.21% 92
2016
Q3
$528K Sell
13,290
-10,590
-44% -$399K 0.17% 81
2016
Q2
$497K Buy
+23,880
New +$817K 0.06% 204
2015
Q4
$199K Buy
+19,530
New +$507K 0.03% 272

Other funds holding EW

WealthPLAN Partners's EW Position: Q4 2025 in Review

WealthPLAN Partners sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 7,010 shares — an estimated $545K sold.

WealthPLAN Partners first reported a position in EW in Q4 2015 and held it in 27 quarters. The position peaked at $859K in Q3 2021. 1,314 funds tracked by Wall St. Rank hold EW as of Q4 2025.

  • WealthPLAN Partners reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
  • WealthPLAN Partners sold 7,010 Edwards Lifesciences shares in Q4 2025, an estimated $545K.
  • WealthPLAN Partners first reported a position in Edwards Lifesciences in Q4 2015 and held it in 27 quarters.
  • WealthPLAN Partners's Edwards Lifesciences position peaked at $859K in Q3 2021.
  • 1,314 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on WealthPLAN Partners's 13F filing for Q4 2025, filed 12 Feb 2026.